Compare Plby Group Inc (PLBY) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Plby Group Inc vs Twist Bioscience Corp — how do they compare? Plby Group Inc trades at $1.16 (market cap $141.97M), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Twist Bioscience Corp is far larger — about 59.3× Plby Group Inc's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals.
| PLBY | TWST | |
|---|---|---|
Market Cap | $141.97M | $8.42B |
Sector | Consumer Cyclical | Health |
52-Week High | $2.71 | $153.10 |
52-Week Low | $1.11 | $24.16 |
Enterprise Value | $287.56M | $8.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PLBY Group trades at $1.18, showing modest daily gains but remains in a technical downtrend. The company demonstrates improving fundamentals with revenue stabilizing around $120M and narrowing losses, though profitability remains elusive. Recent positive developments include Q2 2026 earnings beat, inclusion in Russell indexes, and strategic share repurchases. Analyst sentiment leans bullish with 75% buy ratings, yet technical indicators signal caution with bearish moving averages.
The outlook suggests cautious optimism as PLBY transitions toward profitability, supported by licensing growth and cost management. Key opportunities include brand monetization and market share gains, while risks involve high debt levels, negative equity, and competitive pressures. Investors should monitor execution on profitability targets and debt reduction progress for sustained recovery.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
